Teva Pharma Industries Ltd ADR

Teva Pharma Industries Ltd ADR

Yahoo Finance • yesterday

Teva Leans On A Key Trio To Beat Third-Quarter Forecasts; Shares Hit Buy Zone

Teva stock bounded back into a buy zone Tuesday after third-quarter sales decelerated, but still beat Wall Street's expectations. Continue Reading... Full story

Yahoo Finance • 2 days ago

Sector Update: Healthcare Stocks Ease Late Afternoon

Healthcare stocks eased late Monday afternoon with the NYSE Healthcare Index down 0.1% and the State Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news Full access to Financial Times and MT N... Full story

Yahoo Finance • 15 days ago

Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says

Alvotech (ALVO) has meaningful stock recovery potential as manufacturing progress boosts confidence PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 22 days ago

Nvidia (NVDA) vs. Bumble (BMBL): How the AI Gold Rush is Blinding Investors to Real-Value Gems

The financial markets are currently gripped by a singular obsession: artificial intelligence. This manic focus has pushed sector leaders like Nvidia (NVDA) to staggering heights, with its valuation crossroad vaulting past the $5 trillion m... Full story

Yahoo Finance • 25 days ago

Hospital group files lawsuit to stop 340B rebate pilot again

[An overturned pill bottle spills cash and medicinal capsules] Enrique Yocoyani Aguilar Licona/iStock via Getty Images The American Hospital Association has once again filed a lawsuit to halt a new pilot that tests a revised rebate model... Full story

Yahoo Finance • 26 days ago

Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval

Teva stock surged Friday after the FDA approved its schizophrenia drug, a once-monthly injectable treatment for the disease. Continue Reading... Full story

Yahoo Finance • 28 days ago

QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, has appointed Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective Septembe... Full story

Yahoo Finance • last month

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

The Trump administration has selected 10 companies, including AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]), Amgen (AMGN [https://seekingalpha.com/symbol/AMGN]), Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), and GSK (GSK [http... Full story

Yahoo Finance • last month

Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls

Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled... Full story

Yahoo Finance • last month

Branded Medicines and Pipeline Successes Drive Teva Pharmaceutical Industries’ (TEVA) Margin Expansion

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the "TCW Relative Value Mid Cap Fund". The letter can be downloaded here. Equities advanced in Q2 2026, with the S&P 500 reaching record highs... Full story

Yahoo Finance • last month

Teva and Samsung Bioepis partner on up to six biosimilars

* Samsung Bioepis Co., Ltd. and Teva Pharmaceutical (TEVA [https://seekingalpha.com/symbol/TEVA]) said on Thursday that the companies have entered into a global license, development, and commercialization agreement for up to six potentia... Full story

Yahoo Finance • last month

Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls

Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compile... Full story

Yahoo Finance • last month

Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline

MarketBeat Week in Review – 02/03 - 02/07 Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical co... Full story

Yahoo Finance • 2 months ago

Most Active Options Report: FPS, TEVA, AFL

Forgent Power Solutions Inc (NYSE:FPS) stock is up 12.4% at $35.26 after the company reported record fiscal fourth-quarter results, including an earnings beat. Revenue surged 94% year over year to $462 million, while bookings jumped 375% t... Full story

Yahoo Finance • 2 months ago

Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars

Key Points Interested in Teva Pharmaceutical Industries Ltd.? Here are five stocks we like better. Teva says its "Pivot to Growth" strategy is accelerating as branded medicines gain momentum, generics stabilize, biosimilars expand and deb... Full story

Yahoo Finance • 2 months ago

Temporal Raises $550 Million in Series E Round: NYSE Content Update

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept. 14, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYS... Full story

Yahoo Finance • 2 months ago

Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has agreed to serve as the stalking-horse bidder for substantially all of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)'s assets in a transaction valued at up to $125 million. The deal is struc... Full story

Yahoo Finance • 2 months ago

BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?

A month has gone by since the last earnings report for BridgeBio Pharma (BBIO). Shares have lost about 10.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release,... Full story

Yahoo Finance • 2 months ago

Biotech filed for bankruptcy 11 weeks before its big FDA decision

You can be right about the science and still lose every dollar you put in. That is the hardest lesson in small-cap investing, and it shows up in credit agreements and amendment schedules, not in press releases. Here is how the game usual... Full story

Yahoo Finance • 2 months ago

Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight

DelveInsight Business Research LLP Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & Johnson/Protagonis... Full story